Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics, Singapore s MerLion Collaborate to Find Natural Bug Killers

NEW YORK, Jan. 28--Genome Therapeutics and Singapore's MerLion Pharmaceuticals have begun joint research to identify natural products with antibacterial properties, the two companies said today.

 

MerLion, which is a privately owned spinoff of the privatized Centre for Natural Product Research of the Singapore Institute of Molecular and Cell Biology, will provide a large library of natural products for screening.

 

Genome Therapeutics, which is based in Waltham, Mass., will supply its portfolio of validated pathogenic targets.

MerLion Pharma will use Genome Therapeutics assays to identify chemicals with antibacterial properties that may be valuable as drugs.

 

Research will be overseen by a joint committee from both companies.

 

The two companies will share development costs and rights to clinical development and commercialization of drug candidates.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.